RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+21.23%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$631M
AUM Growth
+$631M
(+21%)
Cap. Flow
+$44.8M
Cap. Flow
% of AUM
7.1%
Top 10 Holdings %
Top 10 Hldgs %
26.93%
Holding
113
New
5
Increased
44
Reduced
29
Closed
9
Top Buys
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$15.5M |
| 2 |
Glaukos
GKOS
|
$10.8M |
| 3 |
Esperion Therapeutics
ESPR
|
$9.48M |
| 4 |
Biogen
BIIB
|
$8.75M |
| 5 |
ELGX
Endologix Inc
ELGX
|
$7.42M |
Top Sells
| 1 |
Teva Pharmaceuticals
TEVA
|
$13.1M |
| 2 |
ARIA
Ariad Pharmaceuticals Inc
ARIA
|
$11.1M |
| 3 |
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
|
$5.44M |
| 4 |
Centene
CNC
|
$4.45M |
| 5 |
Bristol-Myers Squibb
BMY
|
$4.35M |
Sector Composition
| 1 | Healthcare | 92% |
| 2 | Financials | 1.18% |
| 3 | Technology | 0.15% |
| 4 | Energy | 0.12% |
| 5 | Consumer Staples | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Merck
MRK
$210B
| $10.2M | 1.61% |
167,680
+94,320
| +129% | +$5.72M |
|
27
Cigna
CI
$80.2B
| $9.38M | 1.48% |
64,000
-5,000
| -7% | -$732K |
|
28
HCA Healthcare
HCA
$95.4B
| $9.32M | 1.48% |
104,707
| – | – |
|
29
Jazz Pharmaceuticals
JAZZ
$7.99B
| $8.75M | 1.39% |
60,320
+9,400
| +18% | +$1.36M |
|
|
KITE
30
DELISTED
Kite Pharma, Inc.
KITE
| $8.63M | 1.37% |
110,000
+30,000
| +38% | +$2.35M |
|
31
Zimmer Biomet
ZBH
$20.8B
| $8.55M | 1.35% |
72,100
-10,300
| -13% | -$1.22M |
|
32
AbbVie
ABBV
$374B
| $8.47M | 1.34% |
130,000
+15,000
| +13% | +$977K |
|
33
Alkermes
ALKS
$4.95B
| $8.21M | 1.3% |
140,409
+64,810
| +86% | +$3.79M |
|
34
Supernus Pharmaceuticals
SUPN
$2.52B
| $7.2M | 1.14% |
230,000
-20,000
| -8% | -$626K |
|
35
Alnylam Pharmaceuticals
ALNY
$58.6B
| $6.66M | 1.06% |
130,000
-5,000
| -4% | -$256K |
|
|
AET
36
DELISTED
Aetna Inc
AET
| $6.63M | 1.05% |
52,000
-10,000
| -16% | -$1.28M |
|
37
Humana
HUM
$37.5B
| $6.6M | 1.04% |
32,000
-8,000
| -20% | -$1.65M |
|
38
Hologic
HOLX
$14.7B
| $6.38M | 1.01% |
150,000
-10,000
| -6% | -$426K |
|
|
ESRX
39
DELISTED
Express Scripts Holding Company
ESRX
| $6.33M | 1% |
96,000
-15,000
| -14% | -$989K |
|
|
40
Centene
CNC
$14.8B
| $6.24M | 0.99% |
175,186
-124,814
| -42% | -$4.45M |
|
41
Xencor
XNCR
$594M
| $6.22M | 0.98% |
260,000
+35,000
| +16% | +$837K |
|
42
Elevance Health
ELV
$72.4B
| $6.2M | 0.98% |
37,468
-20,789
| -36% | -$3.44M |
|
43
Thermo Fisher Scientific
TMO
$183B
| $6.14M | 0.97% |
40,000
-5,000
| -11% | -$768K |
|
44
Cardinal Health
CAH
$36B
| $6.12M | 0.97% |
75,000
+10,000
| +15% | +$815K |
|
45
Dynavax Technologies
DVAX
$1.19B
| $5.86M | 0.93% |
984,696
+499,696
| +103% | +$2.97M |
|
46
Edwards Lifesciences
EW
$47.7B
| $5.64M | 0.89% |
180,000
-30,000
| -14% | -$941K |
|
47
Cencora
COR
$57.2B
| $5.58M | 0.88% |
63,000
-5,000
| -7% | -$443K |
|
|
SAGE
48
DELISTED
Sage Therapeutics
SAGE
| $5.16M | 0.82% |
+72,659
| New | +$5.16M |
|
49
Abbott
ABT
$230B
| $5.11M | 0.81% |
+115,000
| New | +$5.11M |
|
50
Iovance Biotherapeutics
IOVA
$800M
| $4.84M | 0.77% |
650,000
| – | – |
|